The Ministry of Food and Drug Safety (MFDS) has begun the process of revoking the approval of Medytox's wrinkle-improving drug Meditoxin Inj., driving Medytox to face the biggest crisis since its foundation.
The MFDS announced on April 17 that it will temporarily stop manufacturing, selling and using Medytox's Meditoxin Inj. and will take administrative measures such as revocation of the item's license.
Medytoxin Inj. is a botulinum drug used to treat muscle stiffness and improve wrinkles. Medytoxin Inj. 150 units, 100 units and 50 units were subject to cancellation.
The move comes after the prosecution indicted Medytoxin for obstruction of justice and violation of the Pharmaceutical Affairs Act on the alleged manipulation of test reports on Medytoxin Inj.
Last year, the MFDS asked the prosecution to investigate the alleged manipulation of test reports on Medytoxin Inj., which was tipped off as a public interest report.
The MFDS received the results of the investigation and indictment from the prosecution, including criminal facts, to check the items and violations, and to cancel the item's license for manufacturing and selling drugs in violation of the drug law.
It ordered a temporary suspension of manufacturing and sales in consideration of the period required by administrative procedures in order to protect consumers and prevent them in advance.
It also distributed safety breaking news, requesting immediate suspension of use to medical personnel, the Health Insurance Review and Assessment Service and related organizations.
